

Are your MRI contrast agents cost-effective?

Learn more about generic Gadolinium-Based Contrast Agents.



FRESENIUS  
KABI

caring for life

**AJNR**

***Reply:***

H.A. Valand, F. Huda and R.K. Tu

*AJNR Am J Neuroradiol* 2019, 40 (10) E53

doi: <https://doi.org/10.3174/ajnr.A6231>

<http://www.ajnr.org/content/40/10/E53>

This information is current as  
of April 18, 2024.


## REPLY:

Thank you for providing an opportunity to respond to the 2 letters, the first by Drs Gust and Ishak and the second by Dr Nabavizadeh. Our article focused on imaging findings of neurotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy, an important new therapy for B-cell malignancies. As collective experience increases, so will reporting and understanding the imaging findings. Most published imaging findings of toxicity are in nonimaging journals. Adult neurotoxicity imaging findings were reported in *Cancer Discovery* in December 2017 by Gust et al;<sup>1</sup> *Cancer Discovery* in June 2018 by Santomaso et al;<sup>2</sup> and *CNS Drugs* in November 2018.<sup>3</sup> Subsequent to our May 2019 publication in the *American Journal of Neuroradiology*, *Annals of Neurology* published findings by Gust et al<sup>4</sup> in children and young adults in July 2019 and recently *Brain*, in May 2019, reported findings of acute stroke and hemorrhage.<sup>5</sup> As imaging findings of neurotoxicity are identified and published, neuroradiologists and the imaging community will benefit from continued interest and publication in this area.


<http://dx.doi.org/10.3174/ajnr.A6231>

## REFERENCES

1. Gust J, Hay KA, Hanafi L-A, et al. **Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells.** *Cancer Discov* 2017;7:1404–19 [CrossRef Medline](#)
2. Santomaso BD, Park JH, Salloum D, et al. **Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia.** *Cancer Discov* 2018;8:958–71 [CrossRef Medline](#)
3. Gust J, Taraseviciute A, Turtle CJ. **Neurotoxicity associated with CD19-targeted CAR-T cell therapies.** *CNS Drugs* 2018;32:1091–101 [CrossRef Medline](#)
4. Gust J, Finney OC, Li D, et al. **Glial injury in neurotoxicity after pediatric CD19-directed CAR-T cell therapy.** *Ann Neurol* 2019;86:42–54 [CrossRef Medline](#)
5. Rubin DB, Danish HH, Ali AB, et al. **Neurological toxicities associated with chimeric antigen receptor T-cell therapy.** *Brain* 2019; 142:1334–48 [CrossRef Medline](#)

 **H.A. Valand**

American University of Integrative Sciences  
Brampton, Ontario, Canada

 **F. Huda**

George Washington University Hospital  
Washington, DC

 **R.K. Tu**

Progressive Radiology  
George Washington University, United Medical Center  
Washington, DC